BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 15929121)

  • 1. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
    Migliorati CA; Schubert MM; Peterson DE; Seneda LM
    Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
    Friedrich RE; Blake FA
    Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
    Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
    J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
    Dimitrakopoulos I; Magopoulos C; Karakasis D
    Int J Oral Maxillofac Surg; 2006 Jul; 35(7):588-93. PubMed ID: 16687238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals.
    Magopoulos C; Karakinaris G; Telioudis Z; Vahtsevanos K; Dimitrakopoulos I; Antoniadis K; Delaroudis S
    Am J Otolaryngol; 2007; 28(3):158-63. PubMed ID: 17499130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review.
    Tsai WS; Haghighi K; Placa SJ
    Gen Dent; 2006; 54(3):215-9; quiz 220-2. PubMed ID: 16776417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
    Hay KD; Bishop PA
    N Z Dent J; 2006 Mar; 102(1):4-9. PubMed ID: 16568881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
    Leite AF; Figueiredo PT; Melo NS; Acevedo AC; Cavalcanti MG; Paula LM; Paula AP; Guerra EN
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):14-21. PubMed ID: 16831667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.
    Vescovi P; Nammour S
    Minerva Stomatol; 2010 Apr; 59(4):181-203, 204-13. PubMed ID: 20360666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
    Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws.
    Biasotto M; Chiandussi S; Dore F; Rinaldi A; Rizzardi C; Cavalli F; Di Lenarda R
    Acta Odontol Scand; 2006 Nov; 64(6):348-54. PubMed ID: 17123911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.
    Hansen T; Kunkel M; Weber A; James Kirkpatrick C
    J Oral Pathol Med; 2006 Mar; 35(3):155-60. PubMed ID: 16454811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.